Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;33(10):e13719.
doi: 10.1111/ctr.13719. Epub 2019 Oct 11.

Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation

Vikash Dadlani  1 , Ravinder Jeet Kaur  1 , Mark Stegall  2 , Souzana-Eirini Xyda  1 , Kanchan Kumari  1 , Keisha Bonner  2 , Byron Smith  3 , Prabin Thapa  3 , Patrick G Dean  2 , Yogish C Kudva  1
Affiliations

Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation

Vikash Dadlani et al. Clin Transplant. 2019 Oct.

Abstract

Background: Current therapy for Type 1 diabetes (T1D) is characterized by significant glucose variability (GV). Pancreas transplantation (PT) is performed in certain T1D patients with and without end-stage renal disease. To date, GV has been examined to a limited extent after PT.

Methods: We investigated GV using continuous glucose monitoring (CGM) 3-6 weeks after PT.

Results: Eleven patients had simultaneous kidney pancreas transplantation (SPK), nine pancreas after kidney (PAK), and six pancreas transplantation alone (PTA). Mean CGM showed no difference between SPK, 126.5 ± 13.9, PAK 119.9 ± 12.8, and PTA 131.1 ± 29 mg/dL (P value .6). Percentage of time in range (TIR, 70-180 mg/dL) was 92% for SPK, 93.4% in PAK, and 88.5% in PTA with only 0.3%, 1.5%, and 0.3% of time <70 mg/dL. Percentage >180 mg/dL was 7.9% for SPK, 4.9% PAK, and 11% in PTA. Other measures of GV were similar in the three cohorts. In six patients, CGM was performed before and after PT and improved significantly. GV was also better compared with a matched cohort of T1D patients.

Conclusions: All 3 types of PT resulted in excellent glucose control 3-6 weeks post-procedure. CGM outcomes represent an important objective outcome after PT.

Keywords: Type 1 diabetes; continuous glucose monitor; glycemic variability; hyperglycemia and hypoglycemia; pancreas transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Kovatchev BP. Metrics for glycaemic control - from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425-436.
    1. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther. 2005;7(6):849-862.
    1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
    1. Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
    1. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383-4389.

Publication types

MeSH terms

LinkOut - more resources